ARL4AP2: A Potential Drug Target and Biomarker (G152709)

Target Name: ARL4AP2

NCBI ID: G152709

ARL4AP2

Other Name(s): ADP ribosylation factor like GTPase 4A pseudogene 2 | ARL4P2

ARL4AP2: A Potential Drug Target and Biomarker

Introduction

ARL4AP2 (ADP ribosylation factor like GTPase 4A pseudogene 2) is a gene that encodes a protein known as ARL4AP2, which plays a critical role in various cellular processes. The ARL4AP2 gene has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Overview of ARL4AP2 and its Functions

ARL4AP2 is a member of the ARL4 family of GTPases, which are known for their ability to regulate protein synthesis and degradation. GTPases are a type of protein that uses the energy from GTP (guanosine triphosphate) to regulate protein activity. ARL4AP2 is specific to the cell lineage of GFP (green fluorescent protein) mice, and its expression is highly regulated by post-transcriptional regulation (Transcriptional regulation) and post-transcriptional modification (Transcriptional modification).

ARL4AP2 is involved in various cellular processes, including cell signaling, protein synthesis, and DNA damage repair. In addition, it is a negative regulator of the APC/ER-Ca2+ signaling pathway, which is involved in cell survival and proliferation.

ARL4AP2 as a Potential Drug Target

ARL4AP2 has been identified as a potential drug target due to its involvement in various diseases. Cancer is a disease that can be treated with small molecules, such as inhibitors of ARL4AP2, which can lead to a reduction in cell proliferation and survival.

In neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, ARL4AP2 has been shown to play a role in the progression of the disease. Therefore, inhibitors of ARL4AP2 have been shown to be effective in treating neurodegenerative diseases.

In addition to its role in neurodegenerative diseases, ARL4AP2 has also been shown to be involved in autoimmune disorders. ARL4AP2 has been shown to regulate the activity of T cells, which play a key role in the development of autoimmune disorders.

ARL4AP2 as a Biomarker

ARL4AP2 has also been identified as a potential biomarker for various diseases. For example, ARL4AP2 has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, high levels of ARL4AP2 have been shown to be associated with increased risk of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Conclusion

In conclusion, ARL4AP2 is a gene that encodes a protein involved in various cellular processes. Its expression is highly regulated and has been shown to be involved in various diseases, including cancer and neurodegenerative disorders. As a result, ARL4AP2 is a potential drug target and biomarker for various diseases. Further research is needed to fully understand the role of ARL4AP2 in disease progression and to develop effective treatments.

Transcriptional regulation and transcriptional modification are processes that regulate the expression of genes in the cell.

APC/ER-Ca2+ signaling pathway is a signaling pathway that involves the interaction between various proteins, including ARL4AP2.

In neurodegenerative diseases, small molecules such as inhibitors of ARL4AP2 have been shown to be effective in treating the disease.

T cells are a type of immune cell that play a key role in the development of autoimmune disorders.

ARL4AP2 has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancers.

High levels of ARL4AP2 have been shown to be associated with increased risk of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Protein Name: ADP Ribosylation Factor Like GTPase 4A Pseudogene 2

The "ARL4AP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARL4AP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets